GlobeNewswire·Nov 9, 2026, 4:01 PM ET

IRulya Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IRulya Therapeutics Inc. granted restricted stock units representing 83,513 shares to three new employees on November 9, 2026.
The inducement grants were approved by the Board of Directors to comply with Nasdaq Rule 5635(c)(4) as a material inducement to employment.
Vesting terms include 25% of shares vesting on the last day of the quarter following the first anniversary of the commencement date, with 6.25% vesting quarterly thereafter.
Awards were made under the IRulya Therapeutics Inc. 2026 Inducement Plan \& are subject to continued employment.
The company is developing LAM-001 for pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome post-lung transplant, \& sarcoidosis-associated pulmonary hypertension.
A Phase 2a study in pulmonary hypertension patients is complete, Phase 2 studies in bronchiolitis obliterans syndrome \& pulmonary hypertension associated with interstitial lung disease are ongoing.
A Phase 2 clinical study in sarcoidosis-associated pulmonary hypertension is anticipated to begin in the fourth quarter of 2026.